MX2020007366A - Composiciones y metodos para tratar trastornos de la retina. - Google Patents

Composiciones y metodos para tratar trastornos de la retina.

Info

Publication number
MX2020007366A
MX2020007366A MX2020007366A MX2020007366A MX2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A
Authority
MX
Mexico
Prior art keywords
compositions
methods
retinal disorders
treating retinal
cone
Prior art date
Application number
MX2020007366A
Other languages
English (en)
Inventor
Robin Ali
Alexander Smith
Takaaki Matsuki
Anastasios Georgiadis
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2020007366A publication Critical patent/MX2020007366A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la prevención y/o tratamiento de trastornos de la retina, tales como distrofias de cono, distrofias de cono-barra, en particular acromatopsia.
MX2020007366A 2018-01-12 2019-01-14 Composiciones y metodos para tratar trastornos de la retina. MX2020007366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment
PCT/GB2019/050092 WO2019138250A1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders

Publications (1)

Publication Number Publication Date
MX2020007366A true MX2020007366A (es) 2020-09-03

Family

ID=61256183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007366A MX2020007366A (es) 2018-01-12 2019-01-14 Composiciones y metodos para tratar trastornos de la retina.

Country Status (17)

Country Link
US (1) US11680276B2 (es)
EP (1) EP3737423B1 (es)
JP (1) JP7289306B2 (es)
KR (1) KR20200141435A (es)
CN (1) CN111936172A (es)
AU (1) AU2019206314A1 (es)
BR (1) BR112020014191A2 (es)
CA (1) CA3088079A1 (es)
DK (1) DK3737423T3 (es)
EA (1) EA202091655A1 (es)
GB (1) GB201800546D0 (es)
IL (1) IL275985A (es)
MX (1) MX2020007366A (es)
NZ (1) NZ766316A (es)
PH (1) PH12020551071A1 (es)
SG (1) SG11202006618PA (es)
WO (1) WO2019138250A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
CN113025616B (zh) * 2021-04-21 2023-05-02 中国热带农业科学院橡胶研究所 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用
WO2023039175A2 (en) * 2021-09-09 2023-03-16 Applied Genetic Technologies Corporation Predictors of achromatopsia treatment efficacy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
US20120172419A1 (en) 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CN108410872A (zh) * 2011-01-07 2018-08-17 应用遗传科技公司 用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
WO2015142941A1 (en) 2014-03-17 2015-09-24 Avalanche Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
SG11201707063TA (en) * 2015-03-02 2017-09-28 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
WO2017144080A1 (en) 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Also Published As

Publication number Publication date
EA202091655A1 (ru) 2020-11-20
DK3737423T3 (da) 2024-10-21
KR20200141435A (ko) 2020-12-18
AU2019206314A1 (en) 2020-08-13
EP3737423A1 (en) 2020-11-18
US20200392536A1 (en) 2020-12-17
WO2019138250A1 (en) 2019-07-18
JP7289306B2 (ja) 2023-06-09
SG11202006618PA (en) 2020-08-28
PH12020551071A1 (en) 2021-09-06
CN111936172A (zh) 2020-11-13
EP3737423B1 (en) 2024-09-18
US11680276B2 (en) 2023-06-20
BR112020014191A2 (pt) 2022-02-22
CA3088079A1 (en) 2019-07-18
JP2021510301A (ja) 2021-04-22
IL275985A (en) 2020-08-31
NZ766316A (en) 2024-05-31
GB201800546D0 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
EP3609525A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF INTESTINAL PERMEABILITY DISORDERS
IL272121A (en) Preparation and methods for the treatment of myopia
IL287594A (en) Compositions and methods for the treatment of retinal degeneration
EP3737355A4 (en) COMPOSITIONS AND METHODS OF TREATING A NERVE INJURY
ZA201802606B (en) Compositions for dental varnishes and methods of making and using same
IL292186A (en) Preparations and methods for treating blood disorders
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
PH12018502704A1 (en) Treatment of retinal vascular disease using progenitor cells
MX2022009446A (es) Composiciones para activacion de nrf2 mejorada y sus metodos de uso.
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
PH12017500500A1 (en) C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions
MX2019008763A (es) 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso en tratamiento medico.